REQUEST A DEMO
Total
USD $0.00
Search more companies

Iran Daru Pharmaceutical Company Public Joint Stock (Iran)

Main Activities: Medicinal and Botanical Manufacturing | Pharmaceutical Preparation Manufacturing
Full name: Iran Daru Pharmaceutical Company Public Joint Stock Profile Updated: March 13, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

Iran Daru Pharmaceutical Company was established in 1964 to produce human medicines, including antibiotics, in various dosage forms. It was founded by American investors under the name Cyanamid KBC and changed name to Iran Darou following the nationalization after the Islamic Revolution of 1979. The company produces medicines in the form of tablets, capsules, sachets, gels, creams, solutions and syrups. They are designated for a number of therapeutic categories, such as dermatology, analgesics, gastroenterology and cardiology.

Headquarters
Ayatollah Saidi Expressway, Mo Allem Blvd, End Of Kermani St, P.O Box :13185-753
Tehran; Tehran; Postal Code: 1371658111

Contact Details: Purchase the Iran Daru Pharmaceutical Company Public Joint Stock report to view the information.

Website: http://www.irandaru.com

Basic Information
Total Employees:
Purchase the Iran Daru Pharmaceutical Company Public Joint Stock report to view the information.
Outstanding Shares:
Purchase the Iran Daru Pharmaceutical Company Public Joint Stock report to view the information.
Financial Auditors:
Purchase the Iran Daru Pharmaceutical Company Public Joint Stock report to view the information.
Incorporation Date:
1964
Key Executives
Purchase this report to view the information.
Chairperson
Purchase this report to view the information.
Vice Chairperson
Purchase this report to view the information.
Director / Member of the Management Board
Purchase this report to view the information.
Director / Member of the Management Board
Purchase this report to view the information.
Chief Executive Officer
Ownership Details
Purchase this report to view the information.
1.4%
Purchase this report to view the information.
0.7%
Purchase this report to view the information.
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after Iran Daru Pharmaceutical Company Public Joint Stock report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency IRR. Absolute financial data is included in the purchased report.
Net sales revenue
48.55%
Total operating revenue
49.79%
Operating profit (EBIT)
43.65%
EBITDA
49.9%
Net Profit (Loss) for the Period
53.37%
Total assets
35.22%
Total equity
42.07%
Operating Profit Margin (ROS)
-1.11%
Net Profit Margin
0.55%
Return on Equity (ROE)
3.01%
Debt to Equity Ratio
3.61%
Quick Ratio
0.09%
Cash Ratio
0.05%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?